Table 2.
Treatment interventions of MCL study population with BIM expression and ORR
| Treatment Interventions | Total (%) | Low BIM (<80%) | High BIM (≥80%) | Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) |
|---|---|---|---|---|---|---|---|
| 68 (100%) | 30 (44.1%) | 38 (55.9%) | - | - | - | - | |
| RCHOP-based therapy | 38 (55.9%) | 13 (34.2%) | 25 (65.8%) | 25 (65.8%) | 5 (13.2%) | 1 (2.6%) | 7 (18.4%) |
| CHOP-based therapy | 10 (14.7%) | 7 (70%) | 3 (30%) | 3 (30%) | 0 (0%) | 0 (0%) | 7 (70%) |
| Rituximab alone + combination | 5 (7.4%) | 1 (20%) | 4 (80%) | 2 (40%) | 1 (20%) | 0 (0%) | 2 (40%) |
| DICE therapy | 1 (1.5%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Chlorambucil alone + combination | 4 (5.9%) | 2 (50%) | 2 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (100%) |
| Cyclophosphamide + radiation therapy | 1(1.5%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Radiation therapy only (local) | 3 (4.4%) | 1 (33.3%) | 2 (66.7%) | 2 (66.7%) | 0 (0%) | 1 (33.3%) | 0 (0%) |
| Surgery onlya | 1 (1.5%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
| Treatment unspecifiedb | 1 (1.5%) | 0 (0%) | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| No intervention | 3 (4.4%) | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 2 (66.7%) |
| Status unknownc | 1 (1.5%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) |
a
Astrectomy and splenectomy.
b
Patient was treated, but specific therapy was not documented.
c
No information available on treatment.